SEAGULL HEALTH
Your health,We care!
Ebdarokimab Injection is characterized by definite efficacy (with a PASI75 response rate of nearly 80% at Week 16 and stable efficacy at Week 52), low incidence of adverse reactions (all<5%), no severe hypersensitivity reactions, and convenient administration.
AuthenticGuaranteeFast DeliveryPrivacy Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
